Graves’ disease is an autoimmune condition that causes the thyroid gland to produce excessive amounts of thyroid hormone, leading to a wide range of symptoms that can significantly affect daily life. Treatment focuses on controlling hormone levels, managing symptoms, and preventing long-term complications through medication, radioactive iodine, or surgery.
Understanding Treatment Goals for an Overactive Thyroid
When someone develops Graves’ disease, their immune system begins producing abnormal proteins called thyroid-stimulating immunoglobulins, which act like a faulty switch that keeps the thyroid gland running at full speed without stopping. The thyroid, a small butterfly-shaped organ at the base of the neck, then floods the body with far more hormone than it needs. This hormonal flood speeds up nearly every function in the body, from heartbeat to metabolism, creating a cascade of uncomfortable and potentially dangerous symptoms.[1]
The main goal of treatment is to bring thyroid hormone levels back to normal ranges and keep them stable over time. This helps the heart beat at a regular pace, allows muscles to regain their strength, and gives patients back their ability to sleep, think clearly, and maintain a healthy weight. Treatment also aims to prevent serious complications that can develop when too much thyroid hormone circulates in the bloodstream for extended periods, such as irregular heart rhythms, weakened bones, and in rare cases, a life-threatening condition called thyroid storm.[2]
The choice of treatment depends on several factors that differ from person to person. Doctors consider the patient’s age, the size of the thyroid gland, how severe the symptoms are, whether eye problems have developed, any other medical conditions present, and personal preferences about different treatment approaches. Some patients may also have concerns about pregnancy, which significantly influences treatment decisions. There is no single “best” treatment for everyone—each approach has benefits and drawbacks that need to be carefully weighed.[3]
Most patients start with medications that help control symptoms and reduce hormone production. Others may eventually need more definitive treatments like radioactive iodine or surgery. Medical societies and thyroid specialists have developed guidelines to help doctors choose the most appropriate treatment, but these recommendations are adapted to each individual patient’s situation. Researchers continue to study new approaches and refine existing treatments to improve outcomes and quality of life for people living with this condition.[4]
Standard Medical Treatment
The first line of treatment for most patients with Graves’ disease involves antithyroid medications, which are drugs that interfere with the thyroid gland’s ability to manufacture thyroid hormone. The two main medications used are methimazole and propylthiouracil, often abbreviated as PTU. Methimazole is generally preferred because it can be taken just once per day and tends to cause fewer side effects than PTU. However, PTU may be chosen for women in the first trimester of pregnancy or for patients who cannot tolerate methimazole.[7]
These medications work by blocking the thyroid gland’s use of iodine, which is the raw material the gland needs to produce thyroid hormone. When patients start taking antithyroid drugs, it usually takes several weeks before they begin to feel better, because the medication doesn’t eliminate hormone that’s already been made—it only prevents new hormone from being produced. The existing hormone in the bloodstream must gradually be used up by the body before symptoms improve. Most patients notice significant improvement within six to eight weeks of starting treatment.[13]
Clinical guidelines typically recommend continuing antithyroid medication for 12 to 18 months. During this time, doctors monitor thyroid function regularly through blood tests, adjusting the medication dose as needed to keep hormone levels in the normal range. The hope is that the immune system will calm down during this treatment period and stop attacking the thyroid gland. After 12 to 18 months, many doctors attempt to gradually reduce and then stop the medication to see if the disease remains in remission. Unfortunately, the disease returns in more than half of patients after medication is stopped, requiring them to either restart medication or consider other treatment options.[9]
In addition to antithyroid drugs, doctors often prescribe beta-blocker medications to help control symptoms while waiting for thyroid hormone levels to come down. Beta-blockers don’t treat the underlying disease or lower thyroid hormone levels, but they provide rapid relief from distressing symptoms like rapid heartbeat, trembling hands, anxiety, and excessive sweating. Common beta-blockers used include propranolol and atenolol. These medications work by blocking the effects of excess thyroid hormone on the heart and nervous system, providing symptomatic relief often within hours or days.[13]
Radioactive iodine therapy is the most commonly used treatment in the United States, particularly for patients who don’t achieve remission with antithyroid drugs or who cannot take medication long-term. This treatment involves swallowing a capsule or liquid containing radioactive iodine. Because the thyroid gland naturally concentrates iodine to make thyroid hormone, it absorbs the radioactive iodine, which then slowly destroys thyroid cells from the inside. Over several weeks to months, the thyroid shrinks and produces less hormone.[13]
The radioactive iodine treatment is typically given as a single outpatient dose, calculated based on the size of the thyroid gland and how much iodine it absorbs. Patients must stop antithyroid medications at least two days before treatment to allow the thyroid to take up the radioactive iodine effectively. Some patients may need to stop medication for up to two weeks before treatment for optimal results. After receiving radioactive iodine, thyroid function generally begins to improve within six to eight weeks, though this timing varies considerably among individuals.[13]
The goal of radioactive iodine treatment is usually to destroy enough of the thyroid gland that patients become hypothyroid, meaning their thyroid no longer produces enough hormone on its own. This typically occurs two to three months after treatment. While this might seem counterintuitive, an underactive thyroid is much easier to manage than an overactive one—patients simply take a daily thyroid hormone replacement pill (levothyroxine) for the rest of their lives. This medication is safe, inexpensive, and allows precise control of thyroid hormone levels.[16]
For some patients, particularly those with very severe disease, very large thyroid glands, or those who cannot safely undergo radioactive iodine treatment, thyroid surgery may be recommended. The surgical procedure, called a total thyroidectomy, involves removing the entire thyroid gland through an incision at the base of the neck. This provides immediate and definitive treatment of the overactive thyroid. Like radioactive iodine therapy, surgery results in permanent hypothyroidism requiring lifelong thyroid hormone replacement.[16]
Surgery requires careful preparation. Because operating on a patient with severe hyperthyroidism carries significant risks, including dangerous heart rhythms and a potential thyroid storm during or after surgery, patients must first have their thyroid hormone levels brought as close to normal as possible using antithyroid medications. In some cases, doctors also prescribe special preparations containing high doses of regular (non-radioactive) iodine or the medication lithium for a week or two before surgery to temporarily reduce blood flow to the thyroid gland and make the surgery safer.[9]
The surgical approach has some advantages: it works quickly, completely removes the source of excess hormone, and eliminates the thyroid tissue that could contribute to eye disease (Graves’ ophthalmopathy). However, it also carries surgical risks such as bleeding, infection, damage to nearby structures like the parathyroid glands (which regulate calcium) or the nerves that control the voice box, and requires general anesthesia. When performed by experienced thyroid surgeons, the risk of serious complications is low. Most patients spend one night in the hospital and recover within a few weeks.[7]
Emerging Treatments Being Studied in Clinical Trials
While the standard treatments for Graves’ disease have been used for decades and work reasonably well for most patients, researchers continue searching for new approaches that might work better, have fewer side effects, or specifically target the autoimmune process that causes the disease in the first place. Clinical trials are investigating several innovative treatments that take different approaches to managing this condition.[9]
One promising area of research focuses on using the body’s own immune system more intelligently. Unlike antithyroid drugs that simply reduce hormone production, or radioactive iodine and surgery that destroy the thyroid gland, these experimental approaches try to reprogram the immune system to stop attacking the thyroid. Several drugs originally developed for other autoimmune diseases are being studied to see if they might help patients with Graves’ disease achieve longer-lasting remission without destroying the thyroid gland.[6]
Biologic agents represent a newer class of medications that target very specific parts of the immune system. These are proteins engineered in laboratories that can block certain immune system signals or deplete specific types of immune cells that contribute to the autoimmune attack on the thyroid. One example is rituximab, a medication that reduces the number of B lymphocytes—the immune cells responsible for producing the abnormal antibodies that stimulate the thyroid in Graves’ disease. Small clinical studies have shown some promise, though rituximab is not yet approved or routinely used for Graves’ disease.[6]
Another experimental approach involves medications called immunosuppressive agents that broadly dampen immune system activity. While powerful immunosuppressants like cyclosporine have been studied in patients with severe Graves’ disease or eye disease, their use is limited by significant side effects and the need for careful monitoring. Researchers are working to identify medications that can specifically target the autoimmune process in Graves’ disease without broadly suppressing the entire immune system, which would leave patients vulnerable to infections.[6]
Some clinical trials are investigating whether modifying the duration of antithyroid drug treatment might improve outcomes. Traditional guidelines recommend 12 to 18 months of treatment, but researchers have found that some patients who continue low-dose methimazole for longer periods—sometimes several years—may have better chances of achieving lasting remission. Long-term studies are examining whether extended treatment with low doses is safe and whether it reduces the relapse rate compared to shorter treatment courses.[9]
For patients with significant eye disease (Graves’ ophthalmopathy), clinical trials have tested various treatments to reduce inflammation and swelling behind the eyes. One medication called teprotumumab, a biologic agent that blocks a specific receptor involved in inflammation, recently completed Phase III clinical trials showing it could significantly improve eye bulging and double vision in patients with moderate to severe, active thyroid eye disease. This represents the first medication specifically developed and approved for this complication of Graves’ disease.[6]
Researchers are also investigating the role of selenium supplementation in Graves’ disease management. Selenium is a mineral important for thyroid function and immune system regulation. Some clinical studies have suggested that selenium supplements might help reduce thyroid antibody levels and improve symptoms in patients with autoimmune thyroid disease, though results have been mixed and more research is needed to determine optimal doses and which patients might benefit most.[3]
Clinical trials examining combinations of treatments are also underway. For example, some studies are testing whether combining antithyroid drugs with other medications that modulate the immune system might produce better remission rates than antithyroid drugs alone. Other trials are comparing different sequences of treatment—such as whether starting with radioactive iodine versus starting with medication leads to better long-term outcomes in terms of quality of life and complications.[9]
Most common treatment methods
- Antithyroid medications
- Methimazole: typically taken once daily, blocks thyroid hormone production by preventing the thyroid gland from using iodine
- Propylthiouracil (PTU): blocks thyroid hormone production, may be preferred during early pregnancy or for patients who cannot tolerate methimazole
- Treatment typically continues for 12 to 18 months with regular monitoring through blood tests
- After stopping medication, more than half of patients experience disease recurrence
- Beta-blocker medications
- Propranolol or atenolol: provide rapid symptom relief by blocking effects of excess thyroid hormone on heart and nervous system
- Help control rapid heartbeat, trembling, anxiety, and excessive sweating
- Do not treat the underlying disease or lower thyroid hormone levels
- Used temporarily while waiting for definitive treatments to take effect
- Radioactive iodine therapy
- Single oral dose of radioactive iodine that is absorbed by the thyroid gland
- Slowly destroys overactive thyroid cells over several weeks to months
- Most commonly used treatment in the United States, especially for patients who relapse after medication
- Usually results in permanent hypothyroidism requiring lifelong thyroid hormone replacement
- Outpatient procedure with minimal immediate side effects
- Thyroid surgery (Total thyroidectomy)
- Surgical removal of the entire thyroid gland through a neck incision
- Provides immediate and definitive treatment of overactive thyroid
- Requires careful preparation with medications to normalize thyroid levels before surgery
- Results in permanent hypothyroidism requiring lifelong hormone replacement
- May be recommended for very large thyroid glands, severe disease, or when other treatments are not suitable
- Biologic agents (Experimental)
- Rituximab: reduces B lymphocytes that produce abnormal thyroid-stimulating antibodies
- Teprotumumab: approved for moderate to severe active thyroid eye disease, improves eye bulging and double vision
- Target specific parts of the immune system rather than broadly suppressing immunity




